Wealth Enhancement Advisory Services LLC Has $2.32 Million Stake in Illumina, Inc. (NASDAQ:ILMN)

Wealth Enhancement Advisory Services LLC increased its holdings in shares of Illumina, Inc. (NASDAQ:ILMN) by 82.2% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 17,776 shares of the life sciences company’s stock after acquiring an additional 8,021 shares during the quarter. Wealth Enhancement Advisory Services LLC’s holdings in Illumina were worth $2,318,000 as of its most recent SEC filing.

Other large investors have also added to or reduced their stakes in the company. Versant Capital Management Inc increased its holdings in shares of Illumina by 292.9% in the second quarter. Versant Capital Management Inc now owns 330 shares of the life sciences company’s stock valued at $34,000 after purchasing an additional 246 shares during the last quarter. Industrial Alliance Investment Management Inc. bought a new position in Illumina in the 2nd quarter valued at about $34,000. Massmutual Trust Co. FSB ADV raised its holdings in Illumina by 65.1% in the 3rd quarter. Massmutual Trust Co. FSB ADV now owns 426 shares of the life sciences company’s stock valued at $56,000 after acquiring an additional 168 shares during the period. Itau Unibanco Holding S.A. acquired a new stake in Illumina during the second quarter worth approximately $61,000. Finally, Mizuho Securities Co. Ltd. bought a new stake in shares of Illumina during the second quarter worth approximately $63,000. Institutional investors own 89.42% of the company’s stock.

Illumina Trading Up 3.9 %

NASDAQ ILMN opened at $149.76 on Friday. The firm’s fifty day moving average price is $135.93 and its two-hundred day moving average price is $122.37. The company has a quick ratio of 0.86, a current ratio of 1.11 and a debt-to-equity ratio of 1.04. Illumina, Inc. has a fifty-two week low of $89.00 and a fifty-two week high of $151.40.

Illumina (NASDAQ:ILMN) last issued its quarterly earnings data on Tuesday, August 6th. The life sciences company reported $0.36 earnings per share for the quarter, topping analysts’ consensus estimates of $0.12 by $0.24. The business had revenue of $1.11 billion for the quarter, compared to analyst estimates of $1.09 billion. Illumina had a positive return on equity of 3.08% and a negative net margin of 68.73%. Illumina’s quarterly revenue was down 5.4% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.32 EPS. As a group, sell-side analysts forecast that Illumina, Inc. will post 3.63 earnings per share for the current year.

Analyst Upgrades and Downgrades

ILMN has been the subject of several research reports. Argus raised Illumina from a “hold” rating to a “buy” rating and set a $150.00 price target for the company in a report on Wednesday, August 28th. Royal Bank of Canada restated an “outperform” rating and issued a $252.00 price target on shares of Illumina in a research note on Thursday, October 10th. Piper Sandler dropped their price objective on shares of Illumina from $200.00 to $195.00 and set an “overweight” rating for the company in a research note on Tuesday, August 13th. Leerink Partners increased their target price on shares of Illumina from $160.00 to $200.00 and gave the stock an “outperform” rating in a research report on Thursday, October 17th. Finally, JPMorgan Chase & Co. dropped their price target on shares of Illumina from $130.00 to $125.00 and set a “neutral” rating for the company in a research report on Wednesday, August 7th. One equities research analyst has rated the stock with a sell rating, eight have assigned a hold rating, fourteen have assigned a buy rating and two have assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $154.33.

Illumina Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.